[Magnetic resonance imaging in neuromuscular diseases: benefits and challenges].
Authors
Affiliations (1)
Affiliations (1)
- Laboratoire RMN du CEEN, Institut de myologie, Institut de Myologie, Centre d'Exploration et d'Évaluation Neuromusculaire, Laboratoire d'imagerie et de spectroscopie par RMN, Paris, France.
Abstract
Skeletal muscle magnetic resonance imaging (MRI) plays an increasingly important role in the management of neuromuscular diseases, ranging from diagnostic workup to longitudinal follow-up and therapeutic evaluation. Initially based on qualitative radiological image interpretation, it is evolving towards quantitative approaches that provide a sensitive and objective measure of muscle alterations. The fat fraction (FF), obtained notably using Dixon sequences, and water T2 are currently two widely studied biomarkers integrated into numerous clinical trials. FF allows for the characterization and monitoring of fatty replacement, whereas water T2 is a non-specific marker of disease activity, which can normalize with treatment. Advances in deep learning, accelerated multiparametric acquisitions, and whole-body imaging are driving their deployment. However, inter-center standardization, automation, equipment accessibility, and professional training remain major challenges for their integration into clinical routine.